You are here

Article Text

Article menu
Images in...
Radiological findings in cyclical administration of intravenous pamidronate in children with osteoporosis
Free
  1. C Onwuneme,
  2. K Abdalla,
  3. N Cassidy,
  4. O Hensey,
  5. S Ryan
  1. Children’s University Hospital, Temple Street, Dublin, Ireland
  1. drchike2001{at}yahoo.com

https://doi.org/10.1136/bcr.2007.129692

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    A 5-year-old boy with moderately severe osteogenesis imperfecta and spontaneous fractures was treated with serial courses of intravenous pamidronate. Pamidronate is a second-generation bisphosphonate drug that binds strongly to bone mineral and interferes with bone remodelling by slowing osteoclastic bone resorption. It is used in a cyclic dosage of 1 mg/kg/day intravenously on 3 successive days at 4-monthly intervals. A radiograph of the knee after treatment showed a pattern of parallel dense metaphyseal lines (fig 1A).

    Figure 1
    Figure 1 (A) A 5-year-old boy with osteogenesis imperfecta after cyclic treatment with biphosphonates. AP radiograph of the knee shows dense parallel bands in distal femoral and proximal tibial and fibular metaphyses. (B) A 16-year-old boy with camptodactyly coxavara arthropathy pericarditis syndrome (C-CAP syndrome) and osteoporosis who had cyclic treatment with biphosphonates. AP radiograph of the knee shows dense parallel bands in distal femoral and proximal tibial and fibular metaphyses. Lines are closer to each other than seen in the younger boy.

    A 16-year-old boy with camptodactyly coxavara arthropathy pericarditis syndrome (C-CAP syndrome) also had osteoporosis (Z score −4) with associated spontaneous fractures. After several courses of intravenous pamidronate a radiograph of his knee showed a pattern of parallel dense metaphyseal lines similar to those of the first child but much more closely packed because of less bone growth between courses of the drug in this older patient (fig 1B).

    The value of bisphosphonate administration in paediatric patients for the treatment of osteoporosis and osteogenesis imperfecta has been reported.1–3 We present the radiographic finding of parallel dense metaphyseal lines in two children treated with cyclical intravenous pamidronate. As reported by others, the number of lines corresponded to the number of treatments received and the separation of the lines was determined by the age of the child and the rate of growth of the bone imaged.4

    Acknowledgments

    This article has been adapted from Onwuneme C, Abdalla K, Cassidy N, Hensey O, Ryan S. Radiological findings in cyclical administration of intravenous pamidronate in children with osteoporosis Archives of Disease in Childhood 2007;92:1087

    REFERENCES

    1. ↵
      1. Plotkin H,
      2. Coughlin S,
      3. Kreikemeier R,
      4. et al
      . Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study [correction appears in Dev Med Child Neurol 2006;48(12):1024]. Dev Med Child Neurol 2006; 48(9): 709–12.
      OpenUrl
      1. Henderson RC,
      2. Lark RK,
      3. Kecskemethy HH,
      4. et al
      . Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr 2002; 141(5): 644–51.
      OpenUrl
    3. ↵
      1. Falk MJ,
      2. Heeger S,
      3. Lynch KA,
      4. et al
      . Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 2003; 111(3): 573–8.
      OpenUrl
    4. ↵
      1. Grissom LE,
      2. Harcke HT
      . Radiographic features of bisphosphonate therapy in pediatric patients. Pediatr Radiol 2003; 33(4): 226–9.
      OpenUrl

    Footnotes

    • Parental/guardian informed consent was obtained for publication of the persons’ details in this report.

    • Competing interests: None.